Sign in
4

Changes in Ownership

UroGen Pharma Ltd. Filed Acc 0001209191-22-006385

Chief Financial Officer sold 331 shares at $7.58 ($2,509)

  • Chief Financial Officer acquired 666 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Henderson Molly · Chief Financial Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2022-01-31 Exercise or conversion : show line 1 in the form +666 5,579 D
2022-01-31 Sale : show line 2 in the form −331 $7.58 $2,509 5,248 D
Open-market sales · 331 sh · avg $7.58 · $2,509

Table II: Derivative

3 lines
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2022-01-31 Exercise or conversion : show line 3 in the form Restricted Stock Units −666 1,334 1,334 D
2022-01-31 Grant or award : show line 4 in the form Restricted Stock Units +7,500 7,500 7,500 D
2022-01-31 Grant or award : show line 5 in the form Stock Option (right to buy) +30,000 $7.72 2032-01-31 30,000 30,000 D
Loading xslF345X03/doc4.xml…